Zhou, Y.; Yamamoto, Y.; Xiao, Z.; Ochiya, T. Therapeutic potential of mesenchymal stem/stromal cells-derived exosomes in acute respiratory distress syndrome and COVID-19. Preprints2020, 2020120097. https://doi.org/10.20944/preprints202012.0097.v1
Zhou, Y., Yamamoto, Y., Xiao, Z., & Ochiya, T. (2020). Therapeutic potential of mesenchymal stem/stromal cells-derived exosomes in acute respiratory distress syndrome and COVID-19. Preprints. https://doi.org/10.20944/preprints202012.0097.v1
Zhou, Y., Zhongdang Xiao and Takahiro Ochiya. 2020 "Therapeutic potential of mesenchymal stem/stromal cells-derived exosomes in acute respiratory distress syndrome and COVID-19" Preprints. https://doi.org/10.20944/preprints202012.0097.v1
Coronavirus disease 2019 (COVID-19) caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached a global epidemic across the world after first reported in Wuhan, China’s Hubei province in December 2019. The pandemic is also associated with acute respiratory distress syndrome (ARDS) characterized by excess inflammation, progressive arterial hypoxemia and dyspnea. Mesenchymal stem/ stromal cells (MSCs) have been investigated as treatment for ARDS due to immunomodulatory property. Exosomes derived from MSCs play an important role in paracrine signaling of MSCs, thereby contributed to immunomodulation of the immune microenvironment. Exosomes are emerged as potential alternative to MSC cell therapy with superiority of safety. In this review, we will introduce MSC-derived exosomes and briefly discuss current progress on MSCs and exosomes in ARDS, which may have clinical implications in pathogenesis and treatment of COVID-19.
Biology and Life Sciences, Biochemistry and Molecular Biology
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.